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Substrate engineered, achiral carboxylic acid derivative 2 was
biohydroxylated with various mutants of cytochrome P450
BM-3 to give two out of the four possible diastereoisomers in
high de and ee. The BM-3 mutants exhibit up to 9200 total
turnovers for hydroxylation of the engineered substrate, which
without the protecting group is not transformed by this
enzyme.
Biotransformations are restricted to compounds that are enzyme
substrates. If a target molecule cannot be directly converted by an
enzyme, or if the regio- and/or enantioselectivity of the reaction is
low, at least two strategies can be employed to rectify the situation.
First, given an enzyme system, directed evolution can be exploited
to improve the synthetic outcome.1,2 Alternatively, the substrate
can be engineered to improve its reactivity in a biotransformation,
as in the docking/protecting (d/p) group concept.3,4 Both
approaches have been developed to improve the applicability of
bioconversions in chemical synthesis, especially for preparing
chiral molecules. In this report, we show how protein engineering
and substrate engineering can be combined to improve the
synthetic outcome of a biohydroxylation.
A method for direct biohydroxylation of cyclic carboxylic acids
to produce preparatively valuable starting materials, such as
carboxylic acid 1 to compound 4 (Scheme 1), would be a valuable
addition to an organic chemist’s synthetic ‘‘tool box’’. Carbovir
(Fig. 1), for example, is a carbocyclic nucleoside potentially active
against human HIV.5 4 would be a potentially useful precursor to
this much needed medication. Unfortunately, finding whole cell
systems capable of hydroxylating substances such as 1 has proven
difficult, especially when a specific product stereoselectivity is
required. In addition, these simple carboxylic acids are trouble-
some to purify from complex fermentation/biotransformation
mixtures due to their polarity and lack of UV absorbance.4
The d/p group concept was found to circumvent these problems,
at least in part. Carboxylic acid 1 was chemically modified to give
model compound 2-cyclopentylbenzoxazole 2 (Scheme 1). This
gave a substrate which was easy to manipulate as well as amenable
to biohydroxylation with whole cell systems such as
Cunninghamella blakesleeana DSM 1906.6–8 Protecting group
removal provided end product 4. Regardless of the micro-
organisms and fermentation conditions used, however, only a
single diastereoisomer, (S,S)-4, could be obtained with syntheti-
cally useful diastereoselectivities.6–8 Side products were also formed
during this transformation because the microorganisms used
catalyzed further, undesired transformations, such as oxidation.
Consequently, a new tactic was sought.
Cytochrome P450 BM-3, a medium chain (C12–C18) fatty acid
hydroxylase from Bacillus megaterium, has been engineered to
accept non-natural substrates with enhanced regioselectivity,
enantioselectivity, catalytic rates and total turnover. Mutations in
the active site, for example, enable the enzyme to hydroxylate
alicyclic, heterocyclic, aromatic and even polyaromatic com-
pounds.9–12 In one of our laboratories (FHA), P450 BM-3 has
been engineered for efficient regio- and enantioselective alkane
hydroxylation and alkene epoxidation.13–17 We decided to test
these mutants for their ability to hydroxylate model compound 2.
Whole-cell biotransformations were performed using E. coli
DH5a cells transformed with plasmids carrying the genes of 13
different P450 mutants (see supplementary material{). Results for
the wild type and three mutants are listed in Table 1; the
enantioselectivies obtained using the remaining ten mutants were
similar to 139-3.
Biohydroxylation using the wild type enzyme in E. coli gave very
low enantioselectivity (1.5%, S,S) and high diastereoselectivity
(87%). Mutant 139-3 also afforded (S,S)-3, but in high ee (79%)
and de (96%). Mutant B gave comparable selectivities to 139-3. In
dramatic contrast, mutant 1-12G was found to produce the highly
sought (R,R)-3 in high selectivities (89% ee, 94% de). Although the
isolated yields of 3 were modest, ranging from 0.4% to 15%, these
{ Electronic supplementary information (ESI) available: experimental
details. See http://www.rsc.org/suppdata/cc/b5/b501527h/
*frances@cheme.caltech.edu (Frances H. Arnold)
deraadt@orgc.tu-graz.ac.at (Anna de Raadt)
Scheme 1 The conversion of carboxylic acid 1 to product 4 employing
the docking/protecting group concept.
Fig. 1 Structure of (2)-carbovir.
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transformations have not been optimised with respect to such
parameters as reaction conditions and host organism.
The enzymes from the four strains listed in Table 1 were then
purified for in vitro enzymatic bioconversions. Results are
summarised in Table 2.
Within experimental error, employing the purified enzymes
produced results comparable to those in whole cell reactions.
However, pure wild type BM-3 produced two new results: 3
slightly favored in the (R,R) configuration and an unknown
compound, tentatively identified as a product hydroxylated in the
2 position of the cyclopentane ring, as the major product (y80%,
see supplementary material{).
Total turnover numbers (ttn) and rates of formation of 3 were
measured (Table 3). To determine ttn, the enzymes were diluted to
a concentration at which the P450 is neither oxygen-limited nor
inactivated due to dialysis of the flavins, a likely inactivation
mechanism at low P450 concentrations.18 The three mutant
enzymes catalyse the reaction at approximately the same rate,
which is two orders of magnitude greater than that of the wild
type. The total turnover number varies, however. Mutant B
catalyses about an order of magnitude more turnovers than
wild type.
The P450 BM-3 mutants examined in this work have at least 9
amino acid substitutions, including at least one active site mutation
(A78V) (see supplementary material{). With linear alkanes such as
octane, these mutations increase the regioselectivity of subterminal
hydroxylation.14,16 Mutant 1-12G has the highest regioselectivity
with linear alkanes16 and also exhibits the highest regioselectivity
with substrate 2 (97.6%). Although the mutants were engineered
for the hydroxylation of short, linear alkanes, and not for
substrates such as compound 2, ee’s and de’s of almost 90% were
obtained. The fact that 1-12G produces the (R,R) diastereomer of
3 is notable. This enzyme had previously been shown to catalyse
the hydroxylation of octane primarily to R-2-octanol (39% ee),
while all the other mutants produce mainly S-2-octanol (up to
58% ee).16 In addition to the active site mutation V78A, 1-12G
contains mutations A82L and A328V. Only in this particular
combination do these mutations generate R-2-octanol and R,R-3
from octane and 2, respectively. Consequently, this mutant favors
a different binding conformation of the prochiral molecule 2 in
which the pentyl ring is flipped by 180u relative to the
conformation in all the other mutants.
Wild type P450 BM-3 and the most promising mutants
therefrom (139-3, B and L) were found to be inactive towards
cyclopentanecarboxylic acid 1. Employing substrate engineered,
achiral 2, however, enabled the biohydroxylation, and two out of
the four possible isomers of 3 were prepared in high stereo-
selectivities. This result endorses the use of substrate engineering to
broaden the range of compounds accepted by P450 enzymes. It
also further demonstrates the functional flexibility of P450 BM-3
and supports the notion that the P450 BM-3 can be regarded as a
‘‘one-enzyme-fits-all’’ oxidation catalyst.16
We envisage that total turnover numbers, yields and stereo-
selectivities can be further improved by directly screening BM-3
mutant libraries with substrate 2. Looking further into the future,
it may also be possible to develop strains which produce the two
remaining diastereoisomers of 3. Indeed, we predict that substrate
engineering combined with protein engineering will enable new
applications of biohydroxylation in organic synthesis.
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